AstraZeneca – PSR Ovarian Cancer With a BRCA Mutation

Access Program Information

This is a single-arm, open label, expanded access program to provide access to olaparib
tablets for relapsed high-grade epithelial ovarian cancer patients (including patients with
primary peritoneal and / or fallopian tube cancer) with BRCA mutations (documented mutation
in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious [known or
predicted to be detrimental/lead to loss of function]) who have responded following platinum
based chemotherapy.

Patients may continue to receive study treatment until disease progression as assessed by the
investigator according to local standard clinical practice or any other discontinuation
criteria are met.

Rare Disease: